Humacyte, Inc. (NASDAQ:HUMA) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET
Company Participants
Lauren Marek – LifeSci Advisors
Laura Niklason – President and CEO
Dale Sander – CFO and Chief Corporate Development Officer
Conference Call Participants
Ryan Zimmerman – BTIG
Josh Jennings – TD Cowen & Company
Kristen Kluska – Cantor Fitzgerald
Bruce Jackson – Benchmark Company
Vernon Bernardino – H.C. Wainwright
Operator
Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2024 Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.
I will now turn the call over to Lauren Marek with LifeSci Advisors. Please go ahead.
Lauren Marek
Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.
The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after filing may be accessed from the Investors page of the Humacyte website.
Joining me on today’s call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer, and Dale Sander, Chief Financial Officer and Chief Corporate Development Officer. Dr. Niklason will
Read the full article here
